CLIFF (Cordlife Group) EBIT: $-8.49 Mil (TTM As of Mar. 2026)

What is Cordlife Group EBIT?

Cordlife Group CLIFF 33 EBIT is $-8.49 Mil as of Mar. 2026. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cordlife Group's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-1.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cordlife Group's annualized ROC % for the quarter that ended in Mar. 2026 was -6.58%. Cordlife Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -36.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cordlife Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 140.54%.

Cordlife Group (OTCPK:CLIFF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cordlife Group's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-7.064 * ( 1 - 0% )	/	( (105.93	+	108.935)	/ 2 )
=	-7.064	/	107.4325
=	-6.58 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	156.318	-	10.624	-	( 39.764	-	max(0, 22.419	-	66.007	+	39.764	))
=	105.93

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	156.672	-	12.606	-	( 35.131	-	max(0, 24.359	-	61.659	+	35.131	))
=	108.935

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cordlife Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.236	/	( ( (11.526 + max(1.723, 0))	+	(13.658 + max(1.424, 0)) )	/	2 )
=	-5.236	/	( ( 13.249	+	15.082 )	/	2 )
=	-5.236	/	14.1655
=	-36.96 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(19.582	+	0.757	+	3.296)	-	(10.624	+	0	+	11.288)
=	1.723

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(19.408	+	0.714	+	2.74)	-	(12.606	+	0	+	8.832)
=	1.424

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cordlife Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-8.486	/	-6.038
	=	140.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordlife Group EBIT Related Terms

Cordlife Group EBIT Historical Data

* Premium members only.

The historical data trend for Cordlife Group's EBIT can be seen below:

Cordlife Group EBIT Chart

Cordlife Group Annual Data

Trend

Jun15

Jun16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

5.29

4.18

3.40

-13.91

-8.40

Cordlife Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-1.21	-2.08	-1.79	-3.30	-1.31

CLIFF vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Cordlife Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cordlife Group EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cordlife Group's EV-to-EBIT falls into.

Save Embed

33GF Score

Cordlife Group Ltd CLIFF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cordlife Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.49 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-8.49 Mil mean?

Cordlife Group (CLIFF) has a EBIT of $-8.49 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cordlife Group.

Is Cordlife Group's EBIT too high?

Cordlife Group's current EBIT is $-8.49 Mil. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Cordlife Group's EBIT compare to TMO and DHR?

Cordlife Group's EBIT of $-8.49 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Diagnostics & Research company?

A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cordlife Group. Cordlife Group's current EBIT is $-8.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cordlife Group stock overvalued right now?

Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current EBIT is $-8.49 Mil. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current EBIT is $-8.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

EBIT: $-8.49 Mil
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies SGX:505 SGX:1H3 SGX:1B1 SGX:8YY TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN MTD DGX LH GH MEDP XPAR:ERF

Other Exchanges P8A:Singapore

Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994

Website https://www.cordlife.com

Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.

33GF Score

Get the complete analysis for CLIFF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15

Price

$0.08

GF Value

View CLIFF Analysis

See EBIT data for all stocks →